Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study.

Loupy A, Aubert O, Orandi BJ, Naesens M, Bouatou Y, Raynaud M, Divard G, Jackson AM, Viglietti D, Giral M, Kamar N, Thaunat O, Morelon E, Delahousse M, Kuypers D, Hertig A, Rondeau E, Bailly E, Eskandary F, Böhmig G, Gupta G, Glotz D, Legendre C, Montgomery RA, Stegall MD, Empana JP, Jouven X, Segev DL, Lefaucheur C.

BMJ. 2019 Sep 17;366:l4923. doi: 10.1136/bmj.l4923.

2.

Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance.

Aubert O, Reese PP, Audry B, Bouatou Y, Raynaud M, Viglietti D, Legendre C, Glotz D, Empana JP, Jouven X, Lefaucheur C, Jacquelinet C, Loupy A.

JAMA Intern Med. 2019 Aug 26. doi: 10.1001/jamainternmed.2019.2322. [Epub ahead of print]

3.

Beyond Survival in Solid Organ Transplantation: A Summary of Expert Presentations from the Sandoz 6th Standalone Transplantation Meeting, 2018.

Legendre C, Viebahn R, Crespo M, Dor F, Gustafsson B, Samuel U, Karam V, Binet I, Aberg F, De Geest S, Moes DJAR, Tonshoff B, Oppenheimer F, Asberg A, Halleck F, Loupy A, Suesal C.

Transplantation. 2019 Sep;103(9S1 Suppl 1):S1-S13. doi: 10.1097/TP.0000000000002846. No abstract available.

PMID:
31449167
4.

Anti-IL-2R blockers comparing with polyclonal antibodies: Higher risk of rejection without negative mid-term outcomes after ABO-incompatible kidney transplantation.

Del Bello A, Divard G, Belliere J, Congy-Jolivet N, Lanfranco L, Ricard R, Delas A, Colombat M, Esposito L, Hebral AL, Cointault O, Lefaucheur C, Loupy A, Kamar N.

Clin Transplant. 2019 Aug 1:e13681. doi: 10.1111/ctr.13681. [Epub ahead of print]

PMID:
31369170
5.

Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.

Lefaucheur C, Viglietti D, Bouatou Y, Philippe A, Pievani D, Aubert O, Duong Van Huyen JP, Taupin JL, Glotz D, Legendre C, Loupy A, Halloran PF, Dragun D.

Kidney Int. 2019 Jul;96(1):189-201. doi: 10.1016/j.kint.2019.01.030. Epub 2019 Mar 15.

PMID:
31005275
6.

Archetype Analysis Identifies Distinct Profiles in Renal Transplant Recipients with Transplant Glomerulopathy Associated with Allograft Survival.

Aubert O, Higgins S, Bouatou Y, Yoo D, Raynaud M, Viglietti D, Rabant M, Hidalgo L, Glotz D, Legendre C, Delahousse M, Shah N, Sis B, Campbell P, Mengel M, Jouven X, Van Huyen JD, Lefaucheur C, Loupy A.

J Am Soc Nephrol. 2019 Apr;30(4):625-639. doi: 10.1681/ASN.2018070777. Epub 2019 Mar 14.

PMID:
30872323
7.

An integrated molecular diagnostic report for heart transplant biopsies using an ensemble of diagnostic algorithms.

Parkes MD, Aliabadi AZ, Cadeiras M, Crespo-Leiro MG, Deng M, Depasquale EC, Goekler J, Kim DH, Kobashigawa J, Loupy A, Macdonald P, Potena L, Zuckermann A, Halloran PF.

J Heart Lung Transplant. 2019 Jun;38(6):636-646. doi: 10.1016/j.healun.2019.01.1318. Epub 2019 Feb 6.

PMID:
30795962
8.

Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor: Implications for clinical trials.

Bentall A, Smith BH, Gonzales MM, Bonner K, Park WD, Cornell LD, Dean PG, Schinstock CA, Borrows R, Lefaucheur C, Loupy A, Stegall MD.

Am J Transplant. 2019 Aug;19(8):2274-2283. doi: 10.1111/ajt.15312. Epub 2019 Mar 13.

PMID:
30768833
9.

Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection.

Bouatou Y, Viglietti D, Pievani D, Louis K, Duong Van Huyen JP, Rabant M, Aubert O, Taupin JL, Glotz D, Legendre C, Loupy A, Lefaucheur C.

Am J Transplant. 2019 Jul;19(7):1972-1988. doi: 10.1111/ajt.15299. Epub 2019 Mar 15.

PMID:
30748089
10.

Towards a precision medicine approach to positive crossmatch transplantation: Impact on response to therapy.

Loupy A, Bouatou Y, Aubert O.

Am J Transplant. 2019 Jun;19(6):1611-1613. doi: 10.1111/ajt.15271. Epub 2019 Feb 22. No abstract available.

PMID:
30703855
11.

Antibody-Mediated Rejection of Solid-Organ Allografts.

Lefaucheur C, Loupy A.

N Engl J Med. 2018 Dec 27;379(26):2580-2582. doi: 10.1056/NEJMc1813976. No abstract available.

PMID:
30586534
12.

Exploring the cardiac response to injury in heart transplant biopsies.

Halloran PF, Reeve J, Aliabadi AZ, Cadeiras M, Crespo-Leiro MG, Deng M, Depasquale EC, Goekler J, Jouven X, Kim DH, Kobashigawa J, Loupy A, Macdonald P, Potena L, Zuckermann A, Parkes MD.

JCI Insight. 2018 Oct 18;3(20). pii: 123674. doi: 10.1172/jci.insight.123674.

13.

Antibody-Mediated Rejection of Solid-Organ Allografts.

Loupy A, Lefaucheur C.

N Engl J Med. 2018 Sep 20;379(12):1150-1160. doi: 10.1056/NEJMra1802677. Review. No abstract available.

PMID:
30231232
14.

Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation.

Luque S, Lúcia M, Melilli E, Lefaucheur C, Crespo M, Loupy A, Bernal-Casas D, Gomà M, Jarque M, Crespo E, Montero N, Manonelles A, Cruzado JM, Gil-Vernet S, Grinyó JM, Bestard O.

Am J Transplant. 2019 Feb;19(2):368-380. doi: 10.1111/ajt.15055. Epub 2018 Sep 17.

PMID:
30085394
15.

Correction: Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.

Bouquegneau A, Loheac C, Aubert O, Bouatou Y, Viglietti D, Empana JP, Ulloa C, Murad MH, Legendre C, Glotz D, Jackson AM, Zeevi A, Schaub S, Taupin JL, Reed EF, Friedewald JJ, Tyan DB, Süsal C, Shapiro R, Woodle ES, Hidalgo LG, O'Leary J, Montgomery RA, Kobashigawa J, Jouven X, Jabre P, Lefaucheur C, Loupy A.

PLoS Med. 2018 Jul 27;15(7):e1002637. doi: 10.1371/journal.pmed.1002637. eCollection 2018 Jul.

16.

A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology.

Roufosse C, Simmonds N, Clahsen-van Groningen M, Haas M, Henriksen KJ, Horsfield C, Loupy A, Mengel M, Perkowska-Ptasińska A, Rabant M, Racusen LC, Solez K, Becker JU.

Transplantation. 2018 Nov;102(11):1795-1814. doi: 10.1097/TP.0000000000002366. Review. Erratum in: Transplantation. 2018 Dec;102(12):e497.

17.

Banff Lung Report: Current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR).

Roux A, Levine DJ, Zeevi A, Hachem R, Halloran K, Halloran PF, Gibault L, Taupin JL, Neil DAH, Loupy A, Adam BA, Mengel M, Hwang DM, Calabrese F, Berry G, Pavlisko EN.

Am J Transplant. 2019 Jan;19(1):21-31. doi: 10.1111/ajt.14990. Epub 2018 Aug 1.

PMID:
29956477
18.

Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection.

Viglietti D, Bouatou Y, Kheav VD, Aubert O, Suberbielle-Boissel C, Glotz D, Legendre C, Taupin JL, Zeevi A, Loupy A, Lefaucheur C.

Kidney Int. 2018 Oct;94(4):773-787. doi: 10.1016/j.kint.2018.03.015. Epub 2018 May 22.

PMID:
29801667
19.

Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.

Bouquegneau A, Loheac C, Aubert O, Bouatou Y, Viglietti D, Empana JP, Ulloa C, Murad MH, Legendre C, Glotz D, Jackson AM, Zeevi A, Schaub S, Taupin JL, Reed EF, Friedewald JJ, Tyan DB, Süsal C, Shapiro R, Woodle ES, Hidalgo LG, O'Leary J, Montgomery RA, Kobashigawa J, Jouven X, Jabre P, Lefaucheur C, Loupy A.

PLoS Med. 2018 May 25;15(5):e1002572. doi: 10.1371/journal.pmed.1002572. eCollection 2018 May. Erratum in: PLoS Med. 2018 Jul 27;15(7):e1002637.

20.

A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients.

Jordan SC, Choi J, Aubert O, Haas M, Loupy A, Huang E, Peng A, Kim I, Louie S, Ammerman N, Najjar R, Puliyanda D, Vo A.

Am J Transplant. 2018 Dec;18(12):2955-2964. doi: 10.1111/ajt.14767. Epub 2018 May 14.

PMID:
29637714
21.

The Human Cell Atlas Project by the numbers: Relationship to the Banff Classification.

Moghe I, Loupy A, Solez K.

Am J Transplant. 2018 Jul;18(7):1830. doi: 10.1111/ajt.14757. Epub 2018 Apr 21. No abstract available.

22.

[Identifying the specific causes of kidney allograft loss: A population-based study].

Lohéac C, Aubert O, Loupy A, Legendre C.

Nephrol Ther. 2018 Apr;14 Suppl 1:S39-S50. doi: 10.1016/j.nephro.2018.02.018. French.

PMID:
29606262
23.

Post-Transplant Natural Antibodies Associate with Kidney Allograft Injury and Reduced Long-Term Survival.

See SB, Aubert O, Loupy A, Veras Y, Lebreton X, Gao B, Legendre C, Anglicheau D, Zorn E.

J Am Soc Nephrol. 2018 Jun;29(6):1761-1770. doi: 10.1681/ASN.2017111157. Epub 2018 Mar 30.

24.

Recognition of i-IF/TA as a component of the T cell-mediated rejection spectrum: Unselected population approach vs random case selection.

Lefaucheur C, Viglietti D, Loupy A.

Am J Transplant. 2018 Mar;18(3):771-772. doi: 10.1111/ajt.14667. Epub 2018 Jan 30. No abstract available.

25.

Propensity score-based comparison of the graft failure risk between kidney transplant recipients of standard and expanded criteria donor grafts: Toward increasing the pool of marginal donors.

Querard AH, Le Borgne F, Dion A, Giral M, Mourad G, Garrigue V, Rostaing L, Kamar N, Loupy A, Legendre C, Morelon E, Buron F, Foucher Y, Dantan E.

Am J Transplant. 2018 May;18(5):1151-1157. doi: 10.1111/ajt.14651. Epub 2018 Feb 8.

26.

Antibody-mediated rejection: New approaches in prevention and management.

Montgomery RA, Loupy A, Segev DL.

Am J Transplant. 2018 Jan;18 Suppl 3:3-17. doi: 10.1111/ajt.14584. Erratum in: Am J Transplant. 2018 Jun;18(6):1579.

27.

Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.

Viglietti D, Loupy A, Aubert O, Bestard O, Duong Van Huyen JP, Taupin JL, Glotz D, Legendre C, Jouven X, Delahousse M, Kamar N, Lefaucheur C.

J Am Soc Nephrol. 2018 Feb;29(2):606-619. doi: 10.1681/ASN.2017070749. Epub 2017 Dec 18.

28.

The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.

Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, Nankivell BJ, Halloran PF, Colvin RB, Akalin E, Alachkar N, Bagnasco S, Bouatou Y, Becker JU, Cornell LD, van Huyen JPD, Gibson IW, Kraus ES, Mannon RB, Naesens M, Nickeleit V, Nickerson P, Segev DL, Singh HK, Stegall M, Randhawa P, Racusen L, Solez K, Mengel M.

Am J Transplant. 2018 Feb;18(2):293-307. doi: 10.1111/ajt.14625. Epub 2018 Jan 21.

29.

Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection.

Chen CC, Pouliquen E, Broisat A, Andreata F, Racapé M, Bruneval P, Kessler L, Ahmadi M, Bacot S, Saison-Delaplace C, Marcaud M, Van Huyen JD, Loupy A, Villard J, Demuylder-Mischler S, Berney T, Morelon E, Tsai MK, Kolopp-Sarda MN, Koenig A, Mathias V, Ducreux S, Ghezzi C, Dubois V, Nicoletti A, Defrance T, Thaunat O.

J Clin Invest. 2018 Jan 2;128(1):219-232. doi: 10.1172/JCI93542. Epub 2017 Nov 20.

30.

T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts.

Lefaucheur C, Gosset C, Rabant M, Viglietti D, Verine J, Aubert O, Louis K, Glotz D, Legendre C, Duong Van Huyen JP, Loupy A.

Am J Transplant. 2018 Feb;18(2):377-390. doi: 10.1111/ajt.14565. Epub 2017 Nov 21.

31.

Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.

Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, Aubert O, Orandi BJ, Oppenheimer F, Bestard O, Rigotti P, Reisaeter AV, Kamar N, Lebranchu Y, Duong Van Huyen JP, Bruneval P, Glotz D, Legendre C, Empana JP, Jouven X, Segev DL, Montgomery RA, Zeevi A, Halloran PF, Loupy A.

J Am Soc Nephrol. 2018 Feb;29(2):620-635. doi: 10.1681/ASN.2017050589. Epub 2017 Oct 17.

32.

Response by Loupy et al to Letters Regarding Article, "Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection".

Loupy A, Hidalgo L, Duong JP, Bruneval P, Jouven X, Halloran PF.

Circulation. 2017 Aug 15;136(7):698-699. doi: 10.1161/CIRCULATIONAHA.117.029146. No abstract available.

PMID:
28808152
33.

Building a tissue-based molecular diagnostic system in heart transplant rejection: The heart Molecular Microscope Diagnostic (MMDx) System.

Halloran PF, Potena L, Van Huyen JD, Bruneval P, Leone O, Kim DH, Jouven X, Reeve J, Loupy A.

J Heart Lung Transplant. 2017 Nov;36(11):1192-1200. doi: 10.1016/j.healun.2017.05.029. Epub 2017 May 29.

PMID:
28662985
34.

Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes.

Reeve J, Böhmig GA, Eskandary F, Einecke G, Lefaucheur C, Loupy A, Halloran PF; MMDx-Kidney study group.

JCI Insight. 2017 Jun 15;2(12). pii: 94197. doi: 10.1172/jci.insight.94197. eCollection 2017 Jun 15.

35.

Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.

Gosset C, Viglietti D, Rabant M, Vérine J, Aubert O, Glotz D, Legendre C, Taupin JL, Duong Van-Huyen JP, Loupy A, Lefaucheur C.

Kidney Int. 2017 Sep;92(3):729-742. doi: 10.1016/j.kint.2017.03.033. Epub 2017 May 26.

PMID:
28554738
36.

Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study.

Halloran PF, Reeve J, Akalin E, Aubert O, Bohmig GA, Brennan D, Bromberg J, Einecke G, Eskandary F, Gosset C, Duong Van Huyen JP, Gupta G, Lefaucheur C, Malone A, Mannon RB, Seron D, Sellares J, Weir M, Loupy A.

Am J Transplant. 2017 Nov;17(11):2851-2862. doi: 10.1111/ajt.14329. Epub 2017 May 30.

37.

Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients.

Aubert O, Loupy A, Hidalgo L, Duong van Huyen JP, Higgins S, Viglietti D, Jouven X, Glotz D, Legendre C, Lefaucheur C, Halloran PF.

J Am Soc Nephrol. 2017 Jun;28(6):1912-1923. doi: 10.1681/ASN.2016070797. Epub 2017 Mar 2.

38.

Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.

Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, Kim I, Louie S, Kang A, Peng A, Kahwaji J, Reinsmoen N, Toyoda M, Jordan SC.

Am J Transplant. 2017 Sep;17(9):2381-2389. doi: 10.1111/ajt.14228. Epub 2017 Mar 10.

39.

Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection.

Loupy A, Duong Van Huyen JP, Hidalgo L, Reeve J, Racapé M, Aubert O, Venner JM, Falmuski K, Bories MC, Beuscart T, Guillemain R, François A, Pattier S, Toquet C, Gay A, Rouvier P, Varnous S, Leprince P, Empana JP, Lefaucheur C, Bruneval P, Jouven X, Halloran PF.

Circulation. 2017 Mar 7;135(10):917-935. doi: 10.1161/CIRCULATIONAHA.116.022907. Epub 2017 Feb 1.

PMID:
28148598
40.

From Humoral Theory to Performant Risk Stratification in Kidney Transplantation.

Lefaucheur C, Viglietti D, Mangiola M, Loupy A, Zeevi A.

J Immunol Res. 2017;2017:5201098. doi: 10.1155/2017/5201098. Epub 2017 Jan 2. Review.

41.

Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation.

Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, O'Leary JG, Aluvihare V, Trunečka P, Baccarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M.

Transplantation. 2017 Feb;101 Suppl 2S:S1-S41. doi: 10.1097/TP.0000000000001563. No abstract available.

PMID:
28125449
42.

Long-term Outcomes of Kidney Transplantation in Patients With High Levels of Preformed DSA: The Necker High-Risk Transplant Program.

Amrouche L, Aubert O, Suberbielle C, Rabant M, Van Huyen JD, Martinez F, Sberro-Soussan R, Scemla A, Tinel C, Snanoudj R, Zuber J, Cavalcanti R, Timsit MO, Lamhaut L, Anglicheau D, Loupy A, Legendre C.

Transplantation. 2017 Oct;101(10):2440-2448. doi: 10.1097/TP.0000000000001650.

PMID:
28114171
43.

The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions.

Bruneval P, Angelini A, Miller D, Potena L, Loupy A, Zeevi A, Reed EF, Dragun D, Reinsmoen N, Smith RN, West L, Tebutt S, Thum T, Haas M, Mengel M, Revelo P, Fedrigo M, Duong Van Huyen JP, Berry GJ.

Am J Transplant. 2017 Jan;17(1):42-53. doi: 10.1111/ajt.14112. Epub 2016 Dec 12.

44.

The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.

Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, Nankivell BJ, Colvin RB, Afrouzian M, Akalin E, Alachkar N, Bagnasco S, Becker JU, Cornell L, Drachenberg C, Dragun D, de Kort H, Gibson IW, Kraus ES, Lefaucheur C, Legendre C, Liapis H, Muthukumar T, Nickeleit V, Orandi B, Park W, Rabant M, Randhawa P, Reed EF, Roufosse C, Seshan SV, Sis B, Singh HK, Schinstock C, Tambur A, Zeevi A, Mengel M.

Am J Transplant. 2017 Jan;17(1):28-41. doi: 10.1111/ajt.14107.

45.

Adherence to and Acceptance of Once-Daily Tacrolimus After Kidney and Liver Transplant: Results From OSIRIS, a French Observational Study.

Cassuto E, Pageaux GP, Cantarovich D, Rostaing L, Loupy A, Roche B, Duvoux C, Moreau K, Thervet E, Mazouz H, Bourhis Y, Dharancy S, Kessler M; OSIRIS investigators.

Transplantation. 2016 Oct;100(10):2099-2106. Erratum in: Transplantation. 2017 Jan;101(1):e40-e41.

PMID:
27653227
46.

Early Identification of Patients With Out-of-Hospital Cardiac Arrest With No Chance of Survival and Consideration for Organ Donation.

Jabre P, Bougouin W, Dumas F, Carli P, Antoine C, Jacob L, Dahan B, Beganton F, Empana JP, Marijon E, Karam N, Loupy A, Lefaucheur C, Jost D, Cariou A, Adnet F, Rea TD, Jouven X.

Ann Intern Med. 2016 Dec 6;165(11):770-778. doi: 10.7326/M16-0402. Epub 2016 Sep 13.

PMID:
27618681
47.

Donor-specific antibodies and antibody-mediated rejection in vascularized composite allotransplantation.

Weissenbacher A, Loupy A, Chandraker A, Schneeberger S.

Curr Opin Organ Transplant. 2016 Oct;21(5):510-5. doi: 10.1097/MOT.0000000000000349. Review.

PMID:
27517505
48.

Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss.

Viglietti D, Loupy A, Vernerey D, Bentlejewski C, Gosset C, Aubert O, Duong van Huyen JP, Jouven X, Legendre C, Glotz D, Zeevi A, Lefaucheur C.

J Am Soc Nephrol. 2017 Feb;28(2):702-715. doi: 10.1681/ASN.2016030368. Epub 2016 Aug 4.

49.

C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study.

Viglietti D, Gosset C, Loupy A, Deville L, Verine J, Zeevi A, Glotz D, Lefaucheur C.

Am J Transplant. 2016 May;16(5):1596-603. doi: 10.1111/ajt.13663. Epub 2016 Mar 3.

50.

Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association With Antibody-Mediated Rejection.

Loupy A, Toquet C, Rouvier P, Beuscart T, Bories MC, Varnous S, Guillemain R, Pattier S, Suberbielle C, Leprince P, Lefaucheur C, Jouven X, Bruneval P, Duong Van Huyen JP.

Am J Transplant. 2016 Jan;16(1):111-20. doi: 10.1111/ajt.13529. Epub 2015 Nov 20.

Supplemental Content

Support Center